Literature DB >> 15197337

Aggressive basal cell carcinoma: presentation, pathogenesis, and management.

Hobart W Walling1, Scott W Fosko, Pedram A Geraminejad, Duane C Whitaker, Christopher J Arpey.   

Abstract

Basal cell carcinoma (BCC) is the most common cutaneous skin malignancy. BCC generally has a clinical course characterized by slow growth, minimal soft tissue invasiveness, and a high cure rate. Occasionally, however, BCC behaves aggressively with deep invasion, recurrence, and potential regional and distant metastasis. Several factors, including tumor size, duration, histology, and perineural spread, have been postulated as markers of the aggressive BCC phenotype. It is undetermined whether intrinsic biological factors within certain subsets of BCC predispose these tumors toward an inherently aggressive behavior, or whether any BCC with inadequate early management may assume this phenotype. Review of the pertinent literature on this topic suggests that both intrinsic biological factors and extrinsic management factors play a role in the development and progression of aggressive BCC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15197337     DOI: 10.1023/B:CANC.0000031775.04618.30

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  52 in total

Review 1.  Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.

Authors:  Erica Leavitt; Gary Lask; Stephanie Martin
Journal:  Curr Treat Options Oncol       Date:  2019-11-26

2.  The Effects of Cyclin D1 and Bcl-2 Expressıon on Aggressive Behavior in Basal Cell and Basosquamous Carcinoma.

Authors:  Oya N Sivrikoz; Gülşen Kandiloğlu
Journal:  Iran J Pathol       Date:  2015

3.  Giant Basal Cell Carcinomas Express Neuroactive Mediators and Show a High Growth Rate: A Case-Control Study and Meta-Analysis of Etiopathogenic and Prognostic Factors.

Authors:  Mohammad-Ali Yazdani Abyaneh; Peter Engel; Andrzej Slominski; Bruce Ragsdale; Richard Agag; Daniel Cramer; J Andrew Carlson
Journal:  Am J Dermatopathol       Date:  2017-03       Impact factor: 1.533

Review 4.  Translating cyclooxygenase signaling in patch heterozygote mice into a randomized clinical trial in basal cell carcinoma.

Authors:  Jack L Arbiser
Journal:  Cancer Prev Res (Phila)       Date:  2010-01

5.  Presence of interferon regulatory factor-1 in aggressive and nonaggressive histological variants of Basal cell carcinoma specimens.

Authors:  Nurten Turhan-Haktanir; F Husniye Dilek; Yavuz Demir; Onder Sahin
Journal:  J Cutan Aesthet Surg       Date:  2010-01

6.  Focus on Basal cell carcinoma.

Authors:  Venura Samarasinghe; Vishal Madan; John T Lear
Journal:  J Skin Cancer       Date:  2010-10-24

7.  Vismodegib (erivedge) for advanced Basal cell carcinoma.

Authors:  Chris Fellner
Journal:  P T       Date:  2012-12

8.  Aggressive basal cell carcinoma of the head and neck: challenges in surgical management.

Authors:  Peter J F M Lohuis; Anil Joshi; Pepijn A Borggreven; Lenka Vermeeren; Biljana Zupan-Kajcovski; Abrahim Al-Mamgani; Alfons J M Balm
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-04-11       Impact factor: 2.503

9.  The Use of Noninvasive Optical Coherence Tomography to Monitor the Treatment Progress of Vismodegib and Imiquimod 5% Cream in a Transplant Patient with Advanced Basal Cell Carcinoma of the Nose.

Authors:  Orit Markowitz; Michelle Schwartz
Journal:  J Clin Aesthet Dermatol       Date:  2016-08-01

10.  Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study.

Authors:  Lorenzo Anasagasti-Angulo; Yanelda Garcia-Vega; Silvia Barcelona-Perez; Pedro Lopez-Saura; Iraldo Bello-Rivero
Journal:  BMC Cancer       Date:  2009-07-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.